Hayley Virgil


Combination sacituzumab govitecan/pembrolizumab shows efficacy and safety in metastatic urothelial cancer

February 19, 2022

“These data support further evaluation of antibody-drug conjugate/checkpoint inhibitor combination [therapy] in metastatic urothelial cancer in the platinum-refractory setting and probably in earlier lines of therapy in a different patient population,” says Petros Grivas, MD, PhD.